Search the Newsreel

Form 4 Oncology Institute Inc For: 29 July By Investing.com

This article announces the filing of Form 4 for Oncology Institute Inc. on July 29. It appears to be a standard financial news brief from Investing.com, providing basic information about the regulatory filing. The content itself is minimal, serving primarily as a notification rather …

Oncology Institute (TOI) grants 29,116 RSUs to company director

Oncology Institute (TOI) director Kimberly Jo Tzoumakas was granted 29,116 restricted stock units (RSUs) on July 27, 2026. These RSUs, which vest fully at the company's 2027 annual meeting of stockholders, increase her direct holdings to 46,301 shares. The grant is a form of …

Oncology Institute, Inc. (TOI) awards 33,133 RSUs to director Kaushal Mohit

Oncology Institute, Inc. (TOI) director Kaushal Mohit was granted 33,133 restricted stock units (RSUs) on July 27, 2026, as reported in a Form 4 filing. These RSUs will vest in full at the company’s 2027 annual meeting of stockholders, provided Mohit continues his service. …

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology (CSBR) reported record revenue of $59.4 million for fiscal 2026, driven by its Translational Oncology Solutions business, and achieved positive adjusted EBITDA in all four quarters. The company saw services revenue increase by 12% to $58.7 million, with improved gross margins due …

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology (CSBR) shares dipped by 10.9% following its Q4 earnings report, despite record revenue growth in fiscal 2026 driven by its core research services. The company experienced an operating loss for the full year but saw narrowed diluted losses per share and improved …

Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth?

Champions Oncology (NASDAQ:CSBR) has a cash runway of approximately 12 months based on its current cash burn of US$5.0m and cash reserves of US$4.9m as of April 2026. While this short runway is a concern, its revenue grew by 4.4% last year, and its …

Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk

Cardiff Oncology Inc (CRDF) currently has a risk assessment score of 3.90, ranking 107 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 1.35 indicates higher volatility compared to the S&P 500. The article details various risk metrics …

TOI|Oncology Institute Inc|Price:4.755|Chg%:-0.195

This article provides a comprehensive stock analysis of Oncology Institute Inc (TOI), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes a high institutional ownership and a positive outlook from analysts, with a highest …

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:TOIIW

The Oncology Institute, Inc. (NASDAQ: TOIIW) generated $502.73 million USD in revenue last year. Its top-performing segment was Dispensary, contributing $269.18 million USD, a significant increase from $179.92 million USD the previous year. The United States was the primary geographic contributor, accounting for all …

Kura Oncology (KURA) to Announce Quarterly Earnings on Thursday

Oncology Institute (TOI) to Release Quarterly Earnings on Thursday

Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday

Magnus Concordia Group Limited Auditor Raises 'Going Concern' Doubt

Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Champions Oncology Inc (CSBR), noting its current valuation score of 8.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -31.65, which is significantly below its recent high and above its …

CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440

This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating …

Oncology Institute Inc (TOI) Institutional Confidence

The Oncology Institute Inc (TOI) has an institutional shareholding score of 3.00, placing it 55th out of 75 in its industry. The institutional shareholding proportion has increased by 17.31% quarter-over-quarter to 47.57%. Key institutional shareholders and their recent activity are listed, such as Chernett …

What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders

CG Oncology recently published pivotal Phase 3 BOND-003 data in The Lancet Oncology, showing that its monotherapy, cretostimogene grenadenorepvec, achieved significant complete responses with durable outcomes and a favorable safety profile for high-risk bladder cancer. This positive report strengthens the company's investment narrative by …

Oncology Institute, Inc. (TOI) awards 31,124 RSUs to board director

Oncology Institute, Inc. (TOI) director Mark Stolper has been granted 31,124 restricted stock units (RSUs) as equity compensation. These RSUs, granted at $0.00 per share, vest in full on the date of the company's 2027 annual meeting of stockholders, provided Stolper continues his service. …

Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis

Citius Oncology Inc (CTOR) currently holds a financial score of 7.83, placing it 79th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The report notes that relevant financial data for key metrics like …

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Kura Oncology announced encouraging and durable clinical activity results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma patients. The study showed objective response rates up to 50% and a median progression-free survival of 13 months, with …

Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis

Champions Oncology Inc (CSBR) currently has a financial score of 8.72, ranking 31st out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% year-over-year to 16.56M, while …

ALXO|ALX Oncology Holdings Inc|Price:1.950|Chg%:-0.040

This article provides a comprehensive stock analysis of ALX Oncology Holdings Inc (ALXO), highlighting its relatively weak fundamentals but high growth potential and fair valuation within the Biotechnology & Medical Research industry. The company's lead product candidate, evorpacept, is a CD47 blocking therapeutic, and …

Law firm investigates CG Oncology officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of CG Oncology, Inc. for potential breaches of fiduciary duties through self-dealing. This probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled …

Oncology Institute, Inc. (TOI) grants RSU equity award to director

Oncology Institute, Inc. (TOI) director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs). These RSUs vest in full on the date of the company's 2027 annual meeting of stockholders, contingent on her continued service. Following this award, her direct holdings in …

Oncology Institute (NASDAQ: TOI) awards 30,120 RSUs to director

Oncology Institute director Mark L. Pacala was granted 30,120 restricted stock units (RSUs), increasing his direct holdings to 286,881 shares. These RSUs will vest in full at the company's 2027 annual meeting of stockholders, contingent upon his continued service. This transaction was reported in …

Concord Medical Services Holdings Ltd

The article provides a brief overview of Concord Medical Services Holdings Ltd (CCM), including its stock price and market capitalization. It indicates that relevant data regarding the company's revenue breakdown by business segment and region has not yet been disclosed. The page highlights the …

Kura Oncology (NASDAQ: KURA) revises CEO and executive severance

Kura Oncology (NASDAQ: KURA) has revised the employment agreements for its CEO, CCO, and COO to update severance and change-of-control protections. These new terms define cash severance, COBRA coverage, equity vesting, and stock option exercise rights, differentiating based on whether a termination is linked …

CGON (CGON) insider files to sell 4,303 shares after option exercise

An insider at CG Oncology, Inc. (CGON) has filed a Form 144 notice to sell 4,303 common shares after exercising stock options on July 29, 2026. This sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also details …

ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of ALX Oncology Holdings Inc (ALXO), noting its weak financial status and low operating efficiency with a score of 5.40 out of 385 in the Biotechnology & Medical Research industry. It highlights that relevant financial data for Quality …

Oncology Institute Inc (TOI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oncology Institute Inc (TOI), noting its current valuation score of 7.50, ranking 52 out of 75 in its industry. The company's current P/E ratio is -13.88, which is significantly below its recent high and above its recent …

Liquidity Mapping Around (CGEM) Price Events

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. …

CGON (CGON) insider Ambaw Bellete files to sell 50,000 shares

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intention to sell 50,000 shares of common stock. This planned sale, valued at approximately $3.6 million, is scheduled for on or after July 28, 2026, and is connected …

LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108

LifeSci Capital has reiterated its Buy rating on CG Oncology (CGON.US) and maintained its target price of $108. This indicates continued confidence from the firm in the company's prospects.

ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC

venBio Partners LLC significantly increased its stake in ALX Oncology Holdings Inc. ($ALXO) by 32.8% in Q1, acquiring over 3.18 million additional shares. This makes ALXO the third-largest holding in venBio's portfolio, representing 9.58% of ALXO's total shares. Despite the company missing its latest …

Is Aktis Oncology (AKTS) Fairly Valued After Its Recent Pullback?

Aktis Oncology (AKTS) stock has experienced a recent pullback, dropping 4% in the past week and 17% in the last month, despite year-to-date gains. The company, which focuses on radiopharmaceutical research, trades at a Price-to-Book (P/B) ratio of 2.6x, slightly above the US Biotech …